Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

  • Zheng, De-Jie (Department of Clinical Oncology, Weifang People's Hospital) ;
  • Yu, Guo-Hua (Department of Clinical Oncology, Weifang People's Hospital) ;
  • Gao, Jian-Feng (Department of Clinical Oncology, Weifang People's Hospital) ;
  • Gu, Jun-Dong (Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital)
  • Published : 2013.08.30


Epidermal growth factor receptor (EGFR) is considered to be one of the key driver genes in non-small cell lung cancer (NSCLC). Several clinical trials have shown great promise of EGFR tyrosine kinase inhibitors (TKIs) in the first-line treatment of NSCLC. Many advances have been made in the understanding of EGFR signal transduction network and the interaction between EGFR and tumor microenvironment in mediating cancer survival and development. The concomitant targeted therapy and radiation is a new strategy in the treatment of NSCLC. A number of preclinical studies have demonstrated synergistic anti-tumor activity in the combination of EGFR inhibitors and radiotherapy in vitro and in vivo. In the present review, we discuss the rationale of the combination of EGFR inhibitors and radiotherapy in the treatment of NSCLC.


Non-small cell lung carcinoma;epidermal growth factor receptor;radiation;combine therapy


  1. Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D (2012). Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev, 38, 626-40
  2. Kokubo Y, Gemma A, Noro R, et al (2005). Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer, 92, 1711-9.
  3. Lammering G, Hewit TH, Valerie K, et al (2003). EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene, 22, 5545-53.
  4. Lammering G, Hewit TH, Holmes M, et al (2004). Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radio sensitivity. Clin Cancer Res, 10, 6732-43
  5. Lammering G, Valerie K, Lin PS, et al (2004). Radiation-induced activation of a common variant of EGFR confers enhanced radio resistance. Radiother Oncol, 72, 267-73.
  6. Li C, Iida M, Dunn EF, et al (2010). Dasatinib blocks cetuximab-and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol, 97, 330-7.
  7. Li C, Iida M, Dunn EF, et al (2009). Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 28, 3801-13
  8. Li J, Yen C, Liaw D, et al (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275, 1943-7.
  9. Liang K, Ang KK, Milas L, et al (2003). The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys, 57, 246-54.
  10. Liao HJ, Carpenter G (2009). Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res, 69, 6179-83.
  11. Liccardi G, Hartley JA, Hochhauser D (2011). EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res, 71, 1103-14
  12. Liotta LA, Kohn EC (2001). The microenvironment of the tumour-host interface. Nature, 411, 375-9.
  13. Lo HW (2010). Nuclear mode of the EGFR signaling network: biology, prognostic value, andtherapeutic implications. Discov Med, 10, 44-51.
  14. Lo HW, Hung MC (2006). Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycleprogression, nitric oxide pathway and patient survival. Br J Cancer, 94, 184-8
  15. Lo HW, Xia W, Wei Y, et al (2005). Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res, 65, 338-48.
  16. Lynch TJ, Fenton D, Hirsh V, et al (2009). A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol, 4, 1002-9
  17. Hirata A, Ogawa S, Kometani T, et al (2002). ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermalgrowth factor receptor tyrosine kinase. Cancer Res, 62, 2554-60.
  18. Hirata A, Uehara H, Izumi K, et al (2004). Direct inhibition of EGF receptor activation in vascular endothelial cells bygefitinib ('Iressa', ZD1839). Cancer Sci, 95, 614-8.
  19. Hoshino M, Fukui H, Ono Y, et al (2007). Nuclear expression of phosphorylated EGFR is associated with poor prognosis ofpatients with esophageal squamous cell carcinoma. Pathobiology, 74, 15-21.
  20. Huang SM, Harari PM (2000). Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res, 6, 2166-74.
  21. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
  22. Janmaat ML, Giaccone G (2003). The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc), 39, 61-80.
  23. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
  24. Ji H, Zhao X, Yuza Y, et al (2006). Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 103, 7817-22.
  25. Jiang BH, Jiang G, Zheng JZ, et al (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-induciblefactor 1. Cell Growth Differ, 12, 363-9.
  26. Jiang XD, Dai P, Wu J, et al (2012). Effect of recombinant human endostatin on radiosensitivity in patients withnon-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 83, 1272-7
  27. Jiang XD, Dai P, Wu J, et al (2011). Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice. Lung Cancer, 72, 165-71
  28. Jung IL, Kang HJ, Kim KC, Kim IG (2010). PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-smallcell lung cancer. Int J Mol Med, 25, 517-23.
  29. Karamouzis MV, Grandis JR, Argiris A (2007). Therapies directed against epidermal growth factor receptor in aerodigestivecarcinomas. JAMA, 298, 70-82.
  30. Karar J, Maity A (2011). PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci, 4, 51.
  31. Kim HP, Yoon YK, Kim JW, et al (2009). Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PloS One, 4, e5933
  32. Kobayashi S, Boggon TJ, Dayaram T, et al (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 352, 786-92.
  33. Dittmann K, Mayer C, Fehrenbacher B, et al (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked toactivation of DNA-dependent protein kinase. J Biol Chem, 280, 31182-9.
  34. Dittmann K, Mayer C, Rodemann HP (2005). Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol, 76, 157-61.
  35. Dittmann K, Mayer C, Rodemann HP (2010). Nuclear EGFR as novel therapeutic target: insights into nuclear translocation andfunction. Strahlenther Onkol, 186, 1-6.
  36. Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T (2006). PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol, 1, 629-34.
  37. Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activatingERBB3 signaling. Science, 316, 1039-43.
  38. Ettinger DS (2006). Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 11, 358-73.
  39. Franovic A, Gunaratnam L, Smith K, et al (2007). Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutationalexplanation for its overexpression in human cancer. Proc Natl Acad Sci U S A, 104, 13092-7.
  40. Garcia-Cao I, Song MS, Hobbs RM, et al (2012). Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 149, 49-62.
  41. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al (2001). The Ras radiation resistance pathway. Cancer Res, 61,4278-82.
  42. Han W, Lo HW (2012). Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor sub-cellular locations. Cancer Lett, 318, 124-34.
  43. Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78.
  44. Bouali S, Chretien AS, Ramacci C, et al (2009). P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther, 16, 498-507.
  45. Burger JA, Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107, 1761-7.
  46. Cao Y, Langer R (2008). A review of Judah Folkman’s remarkable achievements in biomedicine. Proc Natl Acad Sci U S A, 105, 13203-5.
  47. Castellino RC, Durden DL (2007). Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point forthe control of angiogenesis in brain tumors. Nat Clin Pract Neurol, 3, 682-93.
  48. Cerniglia GJ, Pore N, Tsai JH, et al (2009). Epidermal growth factor receptor inhibition modulates the microenvironment byvascular normalization to improve chemotherapy and radiotherapy efficacy. PloS One, 4, e6539.
  49. Chen DJ, Nirodi CS (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res, 13, 6555-60.
  50. Christofk HR, Vander HMG, Harris MH, et al (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism andtumour growth. Nature, 452, 230-3.
  51. Chung TD, Broaddus WC (2005). Molecular targeting in radiotherapy: epidermal growth factor receptor. Mol Interv, 5, 15-9.
  52. Das AK, Sato M, Story MD, et al (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66, 9601-8.
  53. Das AK, Chen BP, Story MD, et al (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factorreceptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lungcarcinoma. Cancer Res, 67, 5267-74.
  54. Debucquoy A, Machiels JP, McBride WH, Haustermans K (2010). Integration of epidermal growth factor receptor inhibitors with preoperativechemoradiation. Clin Cancer Res, 16, 2709-14.
  55. Abdollahi A, Hlatky L, Huber PE (2005). Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat, 8, 59-74.
  56. An SJ, Chen ZH, Su J, et al (2012). Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status. PloS One, 7, e40109.
  57. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlyingresponsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
  58. Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 362, 2380-8.
  59. Maity A, Pore N, Lee J, et al (2000). Epidermal growth factor receptor transcriptionally up-regulates vascularendothelial growth factor expression in human glioblastoma cells via a pathwayinvolving phosphatidylinositol 3’-kinase and distinct from that induced byhypoxia. Cancer Res, 60, 5879-86.
  60. Mak RH, Doran E, Muzikansky A, et al (2011). Outcomes after combined modality therapy for EGFR-mutant and wild-type locallyadvanced NSCLC. Oncologist, 16, 886-95.
  61. McKenna WG, Muschel RJ (2003). Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer, 38, 330-8.
  62. Meert AP, Martin B, Delmotte P, et al (2002). The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J, 20, 975-81.
  63. Meyn RE, Munshi A, Haymach JV, et al (2009). Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol, 92, 316-22.
  64. Milosevic M, Fyles A, Hedley D, et al (2004). The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol, 14, 249-58.
  65. Minjgee M, Toulany M, Kehlbach R, et al (2011). K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys, 81, 1506-14.
  66. Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol, 11, 121-8.
  67. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
  68. Morgan S, Grandis JR (2009). ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res, 315, 572-82.
  69. Mukherjee B, McEllin B, Camacho CV, et al (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res, 69, 4252-9.
  70. Nicholson RI, Gee JM, Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer, 37, S9-15.
  71. O’Byrne KJ, Danson S, Dunlop D, et al (2007). Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol, 25, 3266-73.
  72. Okamoto I, Kenyon LC, Emlet DR, et al (2003). Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci, 94, 50-6.
  73. Pao W, Wang TY, Riely GJ, et al (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2, e17.
  74. Peng XH, Karna P, Cao Z, et al (2006). Cross-talk between epidermal growth factor receptor and hypoxia-induciblefactor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem, 281, 25903-14.
  75. Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4, 71-8.
  76. Pore N, Jiang Z, Gupta A, et al (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by bothhypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res, 66, 3197-204.
  77. Rodemann HP, Dittmann K, Toulany M (2007). Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol, 83, 781-91
  78. Sasaki H, Kawano O, Endo K, et al (2007). EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep, 17, 319-23.
  79. Schuurbiers OC, Kaanders JH, der Heijden HF v, et al (2009). The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol, 4, 761-7.
  80. Semenza GL (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci, 33, 207-14.
  81. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-32.
  82. Sherwood LM, Parris EE, Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
  83. Shigematsu H, Lin L, Takahashi T, et al (2005). Clinical and biological features associated with epidermal growth factor receptorgene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.
  84. Sok JC, Coppelli FM, Thomas SM, et al (2006). Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res, 12, 5064-73
  85. Solomon B, Hagekyriakou J, Trivett MK, et al (2003). EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cellcarcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys, 55, 713-23.
  86. Sos ML, Koker M, Weir BA, et al (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res, 69, 3256-61.
  87. Stambolic V, MacPherson D, Sas D, et al (2001). Regulation of PTEN transcription by p53. Mol Cell, 8, 317-25.
  88. Tang Y, Eng C (2006). PTEN autoregulates its expression by stabilization of p53 in aphosphatase-independent manner. Cancer Res, 66, 736-42.
  89. Tomioka A, Tanaka M, De Velasco MA, et al (2008). Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cellsto irradiation. Mol Cancer Ther, 7, 1864-70
  90. Toulany M, Baumann M, Rodemann HP (2003). Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFRdepends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res, 5, 863-72.
  91. Toulany M, Dittmann K, Kruger M, et al (2005). Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol, 76, 143-50.
  92. Wang J, Ouyang W, Li J, et al (2005). Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaBinduced by UV radiation. Cancer Res, 65, 6601-11.
  93. Wang X, Schneider A (2010). HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis, 31, 1202-10.
  94. Wang Y, Yamaguchi H, Hsu J. et al (2010). Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene, 29, 3997-4006.
  95. Weihua Z, Tsan R, Huang WC, et al (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell, 13, 385-93.
  96. Xia W, Wei Y, Du Y, et al (2009). Nuclear expression of epidermal growth factor receptor is a novel prognosticvalue in patients with ovarian cancer. Mol Carcinog, 48, 610-7.
  97. Yamamoto C, Basaki Y, Kawahara A, et al (2010). Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res, 70, 8715-25.
  98. Yamazaki T, Zaal K, Hailey D, et al (2002). Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci, 115, 1791-802.
  99. Yang W, Xia Y, Ji H, et al (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature, 480, 118-22.
  100. Yu J, Zhang SS, Saito K, et al (2009). PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J, 28, 21-33.
  101. Yun CH, Boggon TJ, Li Y, et al (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11, 217-27.
  102. Zander T, Scheffler M, Nogova L, et al (2011). Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F] fluorodeoxyglucose and [(18)F]fluorothymidinepositron emission tomography. J Clin Oncol, 29, 1701-8.
  103. Zhang L, Ge W, Hu K, et al (2012). Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep, 39, 89-95.
  104. Zhong H, Chiles K, Feldser D, et al (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60, 1541-5.
  105. Zhong L, Roybal J, Chaerkady R, et al (2008). Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res, 68, 7237-45.
  106. Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): amulticentre, open-label, randomised, phase 3 study. Lancet Oncol, 12, 735-42.

Cited by

  1. Induction of Indoleamine 2,3-dioxygenase (IDO) Enzymatic Activity Contributes to Interferon-Gamma Induced Apoptosis and Death Receptor 5 Expression in Human Non-small Cell Lung Cancer Cells vol.15, pp.18, 2014,
  2. Clinical Outcome of Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: The Kyung Hee University Medical Center Experience vol.15, pp.4, 2014,
  3. Systematical Analysis of Cutaneous Squamous Cell Carcinoma Network of microRNAs, Transcription Factors, and Target and Host Genes vol.15, pp.23, 2015,
  4. MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance vol.20, pp.1, 2015,
  5. MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients vol.235, pp.3, 2015,
  6. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction vol.48, pp.5, 2016,